Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386764738> ?p ?o ?g. }
- W4386764738 abstract "In CheckMate 649, first-line nivolumab plus chemotherapy prolonged overall survival versus chemotherapy in patients with advanced/metastatic non-human epidermal growth factor receptor 2 (HER2)-positive gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC). We present exploratory patient-reported outcomes (PROs).In patients (N = 1,581) concurrently randomly assigned 1:1 to nivolumab plus chemotherapy or chemotherapy and in those with tumor PD-L1 expression at a combined positive score (CPS) of ≥5, health-related quality of life (HRQoL) was assessed using the EQ-5D and Functional Assessment of Cancer Therapy-Gastric (FACT-Ga), which included the FACT-General (FACT-G) and Gastric Cancer subscale (GaCS). The FACT-G GP5 item assessed treatment-related symptom burden. Longitudinal changes in HRQoL were assessed using mixed models for repeated measures in the PRO analysis population (randomly assigned patients with baseline and ≥1 postbaseline assessments). Time to symptom or definitive deterioration analyses were also conducted.In the PRO analysis population (n = 1,360), PRO questionnaire completion rates were mostly >80% during treatment. Patient-reported symptom burden was not increased with nivolumab plus chemotherapy versus chemotherapy. Mean improved changes from baseline were greater with nivolumab plus chemotherapy versus chemotherapy for FACT-Ga total, GaCS, and EQ-5D visual analog scale in patients with a CPS of ≥5; results were similar for the overall PRO analysis population. In CPS ≥5 and all randomly assigned populations, nivolumab plus chemotherapy reduced the risk of symptom deterioration versus chemotherapy, on the basis of FACT-Ga total score and GaCS; time to definitive deterioration was longer, and the risk of definitive deterioration in HRQoL was reduced with nivolumab plus chemotherapy across EQ-5D and most FACT-Ga measures (hazard ratio [95% CI] <1).Compared with chemotherapy alone, first-line nivolumab plus chemotherapy showed stable or better on-treatment HRQoL in patients with advanced/metastatic non-HER2-positive GC/GEJC/EAC and also showed decreased risk of definitive HRQoL deterioration." @default.
- W4386764738 created "2023-09-16" @default.
- W4386764738 creator A5008674075 @default.
- W4386764738 creator A5011887107 @default.
- W4386764738 creator A5012440329 @default.
- W4386764738 creator A5015799240 @default.
- W4386764738 creator A5019472911 @default.
- W4386764738 creator A5019598772 @default.
- W4386764738 creator A5019892202 @default.
- W4386764738 creator A5020146421 @default.
- W4386764738 creator A5022916059 @default.
- W4386764738 creator A5029343418 @default.
- W4386764738 creator A5031702425 @default.
- W4386764738 creator A5032168190 @default.
- W4386764738 creator A5037920295 @default.
- W4386764738 creator A5039180386 @default.
- W4386764738 creator A5044064524 @default.
- W4386764738 creator A5055732394 @default.
- W4386764738 creator A5066203287 @default.
- W4386764738 creator A5066442450 @default.
- W4386764738 creator A5072717802 @default.
- W4386764738 creator A5073838859 @default.
- W4386764738 creator A5076660441 @default.
- W4386764738 creator A5077895438 @default.
- W4386764738 creator A5087580029 @default.
- W4386764738 creator A5091701897 @default.
- W4386764738 date "2023-09-15" @default.
- W4386764738 modified "2023-09-30" @default.
- W4386764738 title "Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649" @default.
- W4386764738 cites W1566841485 @default.
- W4386764738 cites W1979608435 @default.
- W4386764738 cites W1980935016 @default.
- W4386764738 cites W2010121426 @default.
- W4386764738 cites W2019970875 @default.
- W4386764738 cites W2031121430 @default.
- W4386764738 cites W2035161645 @default.
- W4386764738 cites W2035911356 @default.
- W4386764738 cites W2061843303 @default.
- W4386764738 cites W2066123107 @default.
- W4386764738 cites W2086692084 @default.
- W4386764738 cites W2098428600 @default.
- W4386764738 cites W2109659496 @default.
- W4386764738 cites W2145441649 @default.
- W4386764738 cites W2152362765 @default.
- W4386764738 cites W2160834915 @default.
- W4386764738 cites W2470583568 @default.
- W4386764738 cites W2473786944 @default.
- W4386764738 cites W2513216717 @default.
- W4386764738 cites W2523715715 @default.
- W4386764738 cites W2558269388 @default.
- W4386764738 cites W2570401594 @default.
- W4386764738 cites W2711613673 @default.
- W4386764738 cites W2758552192 @default.
- W4386764738 cites W2767395872 @default.
- W4386764738 cites W2769746786 @default.
- W4386764738 cites W2790556460 @default.
- W4386764738 cites W2805193692 @default.
- W4386764738 cites W2886464002 @default.
- W4386764738 cites W2887666359 @default.
- W4386764738 cites W2904515591 @default.
- W4386764738 cites W2905425294 @default.
- W4386764738 cites W2910830708 @default.
- W4386764738 cites W2912403850 @default.
- W4386764738 cites W2973437854 @default.
- W4386764738 cites W2976652879 @default.
- W4386764738 cites W2990814876 @default.
- W4386764738 cites W3004790717 @default.
- W4386764738 cites W3005292744 @default.
- W4386764738 cites W3006693642 @default.
- W4386764738 cites W3042347895 @default.
- W4386764738 cites W3043703771 @default.
- W4386764738 cites W3082736986 @default.
- W4386764738 cites W3106019786 @default.
- W4386764738 cites W3109873463 @default.
- W4386764738 cites W3123483543 @default.
- W4386764738 cites W3124407053 @default.
- W4386764738 cites W3128646645 @default.
- W4386764738 cites W3171517418 @default.
- W4386764738 cites W3192020910 @default.
- W4386764738 cites W3197262496 @default.
- W4386764738 cites W3212017111 @default.
- W4386764738 cites W4206161022 @default.
- W4386764738 cites W4211007657 @default.
- W4386764738 cites W4214916074 @default.
- W4386764738 cites W4220909053 @default.
- W4386764738 cites W4225713815 @default.
- W4386764738 doi "https://doi.org/10.1200/jco.23.00170" @default.
- W4386764738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37713657" @default.
- W4386764738 hasPublicationYear "2023" @default.
- W4386764738 type Work @default.
- W4386764738 citedByCount "0" @default.
- W4386764738 crossrefType "journal-article" @default.
- W4386764738 hasAuthorship W4386764738A5008674075 @default.
- W4386764738 hasAuthorship W4386764738A5011887107 @default.
- W4386764738 hasAuthorship W4386764738A5012440329 @default.
- W4386764738 hasAuthorship W4386764738A5015799240 @default.
- W4386764738 hasAuthorship W4386764738A5019472911 @default.
- W4386764738 hasAuthorship W4386764738A5019598772 @default.
- W4386764738 hasAuthorship W4386764738A5019892202 @default.
- W4386764738 hasAuthorship W4386764738A5020146421 @default.